Foghorn Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	34.16	19.23	1.32	0.43	0	Upgrade
Revenue Growth (YoY)	77.63%	1357.77%	206.74%	-	-	Upgrade
Gross Profit	34.16	19.23	1.32	0.43	0	Upgrade
Selling, General & Admin	32.37	30.75	21.73	11.25	6.72	Upgrade
Research & Development	109.69	105.62	80.33	57.72	44.36	Upgrade
Operating Expenses	142.06	136.37	102.05	68.96	51.08	Upgrade
Operating Income	-107.91	-117.14	-100.73	-68.53	-51.08	Upgrade
Interest Expense / Income	0	0	1.91	0.98	0.54	Upgrade
Other Expense / Income	-13.71	-8.26	-1.32	-0.71	-0.5	Upgrade
Pretax Income	-94.2	-108.88	-101.32	-68.8	-51.13	Upgrade
Income Tax	4.23	0	0	0	0	Upgrade
Net Income	-98.43	-108.88	-101.32	-68.8	-51.13	Upgrade
Shares Outstanding (Basic)	42	42	37	11	4	Upgrade
Shares Outstanding (Diluted)	42	42	37	11	4	Upgrade
Shares Change	0.92%	11.89%	236.49%	163.53%	42.23%	Upgrade
EPS (Basic)	-2.34	-2.62	-2.73	-6.23	-12.20	Upgrade
EPS (Diluted)	-2.34	-2.62	-2.73	-6.23	-12.20	Upgrade
Free Cash Flow	-119.33	192.4	-53.56	-47.22	-47.3	Upgrade
Free Cash Flow Per Share	-2.84	4.63	-1.44	-4.27	-11.28	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	Upgrade
Operating Margin	-315.93%	-609.20%	-7637.15%	-15937.44%	-	Upgrade
Profit Margin	-288.17%	-566.27%	-7681.58%	-16000.00%	-	Upgrade
Free Cash Flow Margin	-349.38%	1000.63%	-4060.88%	-10981.16%	-	Upgrade
EBITDA	-85.54	-100.98	-91.9	-62.29	-48.8	Upgrade
EBITDA Margin	-250.44%	-525.18%	-6967.32%	-14486.74%	-	Upgrade
Depreciation & Amortization	8.66	7.9	7.52	5.53	1.79	Upgrade
EBIT	-94.2	-108.88	-99.41	-67.82	-50.59	Upgrade
EBIT Margin	-275.80%	-566.27%	-7537.07%	-15772.33%	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).